FDA Could Delay Part 11 Revision to 'Get It Right,' Official Says

Drug Industry Daily
KEYWORDS FDA / Technology

The FDA is unlikely to complete its long-awaited revision of 21 CFR Part 11 — which regulates the use of electronic records and signatures — by the end of the year as industry observers had expected, an agency official said this month.

To View This Article:


Subscribe To Drug Industry Daily